CyFlow™ CD23 Purified

CyFlow™ CD23 Purified
Target Species: Human
Antigen: CD23
Field of Interest: Immunophenotyping
Clone: EBVCS-5
Regulatory Status: RUO
Alternative Name: BLAST-2, FcɛRII
Application: Flow cytometry, Immunoprecipitation
Format/Fluorochrome: Purified
Species of Origin: Mouse
Clonality: monoclonal
Isotype: IgG1
Product number: BV210369

For Research Use Only

$120.00 USD*

Price excludes any applicable taxes plus shipping costs

Concentration Unit mg/mL Concentration 1 Quantity 0.1 mg Immunogen... more
CyFlow™ CD23 Purified
Concentration Unitmg/mL
Concentration1
Quantity0.1 mg
ImmunogenEBV-transformed human cells
SpecifityThe mouse monoclonal antibody EBVCS-5 recognizes an epitope located in the stalk region of human low affinity IgE receptor (CD23) between the 37 and 25 kDa cleavage sites.
Background InformationCD23 (Fc ε RII), the low affinity IgE receptor, is a 45 kDa type II membrane glycoprotein expressed more or less on eosinophils, follicular dendritic cells, Langerhans cells, mature B cells (mainly upon activation), EBV-transformed lymphoblasts, monocytes, and subpopulation of platelets. A soluble form of 37 kDa and other its fragments were also described. CD23 mediates IgE-dependent cytotoxicity by eosinophils and macrophages, and downregulates IgE secretion in response to high levels of IgE, involving release of pro-inflammatory cytokines.
Storage BufferThe reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.1% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Ling NR, Stevenson FK, Brown B: Urinary excretion of CD23 antigen in normal individuals and patients with chronic lymphocytic leukaemia (CLL). Clin·Exp·Immunol. 1991·Dec; 86(3):360‑6. <·PMID:·1721010·> | Yamaoka KA, Arock M, Issaly F, Dugas N, Le Goff L, Kolb JP: Granulocyte macrophage colony stimulating factor induces Fc epsilon RII/CD23 expression on normal human polymorphonuclear neutrophils. Int·Immunol. 1996·Apr; 8(4):479‑90. <·PMID:·8722638·> | Rumi C, Rutella S, Leone G, Bonini S: Fc‑RII/CD23 receptor on circulating human eosinophils. Blood. 1998·Apr·1; 91(7):2621‑2. <·PMID:·9516167·> | Belleau JT, Gandhi RK, McPherson HM, Lew DB: Research upregulation of CD23 (FcepsilonRII) expression in human airway smooth muscle cells (huASMC) in response to IL‑4, GM‑CSF, and IL‑4/GM‑CSF. Clin·Mol·Allergy. 2005·May·20; 3:6. <·PMID:·15907205·> | Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S: Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin·Cancer·Res. 2007·Aug·1; 13(15‑1):4448‑55. <·PMID:·17671129·>

Article successfully added.